Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.
Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
The Alain Labrique Lab conducts research on infectious diseases and public health. Our team studies the various factors that lead to maternal and neonatal mortality, particularly in underserved populations in South Asia, using the tools of infectious disease epidemiology, molecular biology and biostatistics. We work to better understand factors such as the interface of micronutrient deficiency and maternal/infant mortality and the prevention of nosocomial infections through mechanistic or nutritional interventions. We also have a longstanding interest in technologies that may enable early detection of disease.
The Amita Gupta Lab focuses on drug trials to prevent and treat HIV, tuberculosis (TB) and other co-morbidities in adults, including pregnant women and children who reside in low-income settings. We also conduct cohort studies assessing HIV, inflammation and nutrition in international settings; TB in pregnancy; and risk factors for TB in India (CTRIUMPH). We collaborate with several faculty in the Center for TB Research, Division of Infectious Diseases and the School of Public Health.
The long-term goal of the Caren L. Freel Meyers Laboratory is to develop novel approaches to kill human pathogens, including bacterial pathogens and malaria parasites, with the ultimate objective of developing potential therapeutic agents.
Toward this goal, we are pursuing studies of bacterial isoprenoid biosynthetic enzymes comprising the methylerythritol phosphate (MEP) pathway essential in many human pathogens. Studies focus on understanding mechanism and regulation in the pathway toward the development of selective inhibitors of isoprenoid biosynthesis. Our strategies for creating new anti-infective agents involve interdisciplinary research in the continuum of organic, biological and medicinal chemistry. Molecular biology, protein expression and biochemistry, and synthetic chemistry are key tools for our research.
The Carrie Herzke Lab focuses on patient safety and quality improvement. We’re also interested in infectious diseases, particularly infection control, and the education of resident and medical students.
In conjunction with the Molecular Imaging Center, the Center for Infection and Inflammation Imaging Research core provides state-of-the art small animal imaging equipment, including PET, SPECT, CT and US, to support the wide range of scientific projects within the diverse research community of the Johns Hopkins University and beyond. Trained technologists assist investigators in the use of these facilities.
A. Laboratory activities include the use of accelerator mass spectrometry (AMS) techniques to measure intracellular drugs and drugs metabolites. AMS is a highly sensitive method for detecting tracer amounts of radio-labeled molecules in cells, tissues, and body fluids. We have been able to measure intracellular zidovudine triphosphate (the active anabolite of zidovudine) in peripheral blood mononuclear cells from healthy volunteers given small doses of 14C-zidovudine, and have directly compared the sensitivity of AMS to traditional LC/MS methods carried out in our laboratory.
B. Clinical research activities investigate the clinical pharmacology of new anti-HIV therapies and drug combinations. Specific drug classes studied include HIV reverse transcriptase inhibitors, protease inhibitors, entry inhibitors (selective CCR5 and CXCR4 antagonists), and integrase inhibitors. Scientific objectives of clinical studies include characterization of early drug activity, toxicity, and pharmacok...inetics. Additional objectives are characterization of pathways of drug metabolism, and identification of clinically significant harmful and beneficial drug interactions mediated by hepatic and intestinal cytochrome P450 isoforms. view more
Dr. Christine Durand, assistant professor of medicine and oncology and member of the Johns Hopkins Kimmel Cancer Center, is involved in clinical and translational research focused on individuals infected with HIV and hepatitis C virus who require cancer and transplant therapies. Her current research efforts include looking at outcomes of hepatitis C treatment after solid organ transplant, the potential use of organs from HIV-infected donors for HIV-infected solid organ transplant candidates, and HIV cure strategies including bone marrow transplantation.
Dr. Durand is supported by multiple grants:
• R01 from the National Institute of Allergy and Infectious Diseases (NIAID) to study HIV-to-HIV organ transplantation in the US.
• K23 from the National Cancer Institute (NCI) to study antiretroviral therapy during bone marrow transplant in HIV-1 infection.
• U01 from the NIAID to study HIV-to-HIV deceased donor kidney transplantation.
U01 from the NIAID to study HIV-to-HIV deceased ...donor liver transplantation. view more
Research in the Craig W. Hendrix Lab concentrates on the chemoprevention of HIV infection, clinical pharmacology of antiviral drugs, drug interactions, and oral, topical and injectable HIV microbicide development. Our lab conducts small, intensive sampling studies of PK and PD of drugs for HIV prevention with a focus on developing methods to better understand HIV and drug distribution in the male genital tract, female genital tract and lower gastrointestinal tract. We also support numerous HIV pre-exposure prophylaxis development studies from phase I to phase III, largely as leader of the Pharmacology Core Laboratory of both the Microbicide Trial Network and HIV Prevention Trials Network.
The David Dowdy Lab conducts research in the field of infectious disease epidemiology. We use an interdisciplinary approach that involves infectious disease modeling, health economics, classical epidemiology, and operational and implementation science. Much of our work explores the diagnosis and treatment of tuberculosis. We also have a longstanding interest in “translational epidemiology,” with a goal of developing methods to help medical professionals who use epidemiological data make decisions that are in the best interest of patients and public health.
Research in the David Sack Lab focuses on enteric infections. Our team has worked to develop laboratory detection methods to better understand the epidemiology of these agents. We also work to create appropriate clinical management strategies, such as antibiotics and rehydration methods, for enteric infections. Our work has included participating in the development of vaccines for a range of bacterial infections, including rotavirus, cholera and enterotoxigenic E. coli.
Research in the Elizabeth Tucker Lab aims to find treatments that decrease neuroinflammation and improve recovery, as well as to improve morbidity and mortality in patients with infectious neurological diseases. We are currently working with Drs. Sujatha Kannan and Sanjay Jain to study neuroinflammation related to central nervous system tuberculosis – using an animal model to examine the role of neuroinflammation in this disease and how it can differ in developing brains and adult brains. Our team also is working with Dr. Jain to study noninvasive imaging techniques for use in monitoring disease progression and evaluating treatment responses.
Research in the Eric Nuermberger Lab focuses primarily on experimental chemotherapy for tuberculosis. We use proven murine models of active and latent tuberculosis infection to assess the effectiveness of novel antimicrobials. A key goal is to identify new agents to combine with existing drugs to shorten tuberculosis therapy or enable less frequent drug administration. We're also using a flow-controlled in vitro pharmacodynamic system to better understand the pharmacodynamics of drug efficacy and the selection of drug-resistant mutants during exposure to current agents.
Research in the Erica Johnson Lab investigates infection control in military deployment environments as well as infections that are associated with combat trauma. We explore topics such as HIV outcomes, gender-based health issues and disparities in care.
Work in the Graham Mooney Lab focuses on the history of public health interventions as well as the impact of public health policies on population health outcomes. Our research includes topics such as the history of public health in the United Kingdom and United States during the 19th and 20th centuries, and the historical geographies of health and medicine. We also explore infectious disease surveillance and control and historical epidemiology and demography.
Our IndoUS team, based both in Baltimore and in India, specializes in international clinical research (cohort studies and clinical trials), public health implementation science and education in infectious diseases, HIV/AIDS, tuberculosis (TB), vaccine preventable illnesses, antimicrobial resistant infections, and more recently COVID. Since 2003, our work has been focused primarily on India, where we are engaged in several Indo-JHU and international research collaborations. We partner with several leading medical and research institutions in India (e.g. BJGMC, DY Patil, Hinduja Hospital, KEM, Bharati Vidyapeeth, NIRT, JIPMER, CMC, Medanta, IISER, YRG, IIT), as well as others in sub-Saharan Africa, US and Brazil. We are actively involved in the following consortia: 1) Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. 2) RePORT International T...B Research Consortium, a multilateral global consortia for TB research, 3) US NIH funded multi-country HIV and TB trials consortia of the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT) Network, 4) NIH and AmFAR funded IeDea HIV/TB Working Group and the Treat Asia-IeDEA HIV and TB epidemiology databases, and 5) CDC SHEPHERD AMR studies.
Our group has been awarded research grants from the US NIH, US CDC, UNITAID, Indian government, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. view less
Work in the Joel Blankson Lab explores the mechanism of control of HIV-1 replication in a cohort of patients known as elite controllers or elite suppressors. These patients are HIV-1 seropositive but maintain levels of viremia that are below the limit of detection of standard clinical assays. We feel that elite suppressors represent a potential model for a therapeutic HIV vaccine. Our central hypothesis is that many of these patients are infected with fully replication-competent HIV-1 isolates that are held in check by the immune system. To test this hypothesis, we are studying many different host and viral factors in these patients.
Research in the Jonathan Golub Lab focuses primarily on the epidemiology of tuberculosis (TB), specifically in patients infected with HIV. We work with the CDC to explore potential delays in TB diagnoses as well as the risk factors that contribute to death from TB in the United States. Our research also includes ongoing studies of HIV and TB patients in Brazil and South Africa.
Research in the Joseph Cofrancesco Jr. Lab focuses primarily on health care for HIV-positive patients. Our recent studies have explored topics such as HIV antiretroviral treatments, HIV resistance and the long-term complications of HIV treatment. In addition, we are part of the U.S. Fat Redistribution and Metabolism (FRAM) study and have had a long-standing involvement in projects that examine metabolic and fat complications in Thailand.
Research in the Justin Bailey Lab explores immune responses against hepatitis C virus (HCV), particularly neutralizing antibody responses, with the goal of guiding vaccine development against the virus. Recent studies have demonstrated that early and broad neutralizing antibody (nAb) responses against HCV are associated with HCV clearance, suggesting a key role for nAb in limiting HCV replication. The findings of this research will enhance understanding of how HIV infection may contribute to the lower rate of HCV clearance in HCV/HIV coinfected individuals, and the results could have implications for persistence of other viruses commonly occurring as coinfections with HIV.
The Karakousis Lab is primarily focused on understanding the molecular basis of Mycobacterium tuberculosis persistence and antibiotic tolerance. A systems biology-based approach, including the use of several novel in vitro and animal models, in combination with transcriptional, proteomic, genetic, imaging, and computational techniques, is being used to identify host cytokine networks responsible for immunological control of M. tuberculosis growth, as well as M. tuberculosis regulatory and metabolic pathways required for bacillary growth restriction and reactivation. In particular, we are actively investigating the regulatory cascade involved in the mycobacterial stringent response. Another major focus of the lab is the development of host-directed therapies for TB, with the goal of shortening treatment and improving long-term lung function. Additional research interests include the development of novel molecular assays for the rapid diagnosis of latent TB infection and active TB diseas...e, and for the detection of drug resistance. view more
Research in the Kathleen Page Lab examines the impact of bovine colostrum (BC) on immune activation and HIV susceptibility, and aims to develop a point-of-care diagnostic test for histoplasmosis.
Research in the Kawsar Rasmy Talaat Lab focuses on international health and parasitology, with an emphasis on vaccines, avian influenza and pandemic influenza. Our team conducts clinical trials of vaccines for a range of diverse pathogens, including flu strains that have the potential to reach pandemic status. Our studies seek to evaluate the safety and immunogenicity of vaccine candidates. We also have a longstanding interest in tropical medicine.
The Lamichhane Lab strives to understand the fundamental mechanisms used by Mycobacterium tuberculosis to survive, grow and cause disease. Although our lab uses genetic and biochemical approaches to study this organism, we pursue questions irrespective of the expertise required to answer those questions. We work to identify the essential components of the peptidoglycan layer and how the physiology of this layer is maintained. We also explore what non-coding RNAs exist in M. tuberculosis and investigate what their relevance is to the physiology and virulence of this pathogen.
Research in the Larry Chang Lab focuses on innovative, multidisciplinary and pragmatic approaches to impacting the HIV/AIDS pandemic. Our research investigates ways to improve HIV/AIDS care in low- and middle-income settings through strategies that include quantitative methods, qualitative methods, community-based trial designs, and behavioral science and economic evaluations. In addition, we research mobile technologies for health (mHealth) strategies for improving global public health and clinical care, including novel applications for intimate-partner violence intervention, dengue surveillance, and HIV care, surveillance and prevention.
Research in the Mark Sulkowski Lab focuses on hepatitis B and hepatitis C. We've conducted clinical research related to the management of viral hepatitis, including novel agents. Other studies focus on adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.
The Maryam Jahromi Lab researches infectious diseases such as influenza, tuberculosis, endocarditis, viral hemorrhagic fevers, brucellosis, Clostridium difficile and Crimean-Congo hemorrhagic fever. We are particularly interested in the impact of the influenza vaccine on systemic inflammation. Recent areas of focus include the relationship between influenza vaccination and cardiovascular outcomes, the emergence of Crimean-Congo hemorrhagic fever in Iran, and prospects for vaccines and therapies for Crimean-Congo hemorrhagic fever.
Work in the Maunank Shah Lab focuses on infectious disease modeling and health economics, and seeks to investigate new strategies for diagnosing HIV and tuberculosis (TB) in areas with limited resources, both domestically and abroad. Our primary focus is TB diagnostics, with studies examining the diagnostic test accuracy, cost-effectiveness and programmatic impact of emerging diagnostics. We have developed mobile health initiatives to incorporate video-based therapy for TB treatment, and we have a longstanding interest in interventions that help to reduce or prevent HIV transmission.
Research in the Michael Melia Lab focuses primarily on nocardia infections, Lyme disease and hepatitis C. Our studies have included key topics such as risk factors for incident infections during hepatitis C treatment, racial differences in eligibility for hepatitis C treatment and misdiagnosis of Lyme arthritis using the Borrelia burgdorferi immunoblot testing method. We also have a longstanding interest in medical education and work on curriculum to improve the quality of education for medical students and interns.
The Natasha Chida Lab investigates methods for using education and curriculum development to improve patient outcomes worldwide, primarily by optimizing education of physicians-in-training. Most recently, our team has worked to develop and evaluate an assessment tool for evaluating internal medicine residents’ understanding of tuberculosis diagnostics. Previous research includes a retrospective cohort study on the high proportion of extrapulmonary TB in a low-prevalence setting as well as an analysis of ways to define clinical excellence in adult infectious disease practice.
Work in the Peter Agre Lab focuses on the molecular makeup of human diseases, particularly malaria, hemolytic anemias and blood group antigens. In 2003, Dr. Agre earned the Nobel Prize in Chemistry for discovering aquaporin water channels. Building on that discovery, our recent research has included studies on the protective role of the brain water channel AQP4 in murine cerebral malaria, as well as defective urinary-concentrating ability as a result of a complete deficiency in aquaporin-1. We also collaborate on scientific training and research efforts with 20 Baltimore-area labs and in field studies in Zambia and Zimbabwe.
Research in the Photini Sinnis Lab explores the fundamental biology of the pre-erythrocytic stages of malaria. Our team is focused on the sporozoite stage of Plasmodium, which is the infective stage of the malaria parasite, and the liver stages into which they develop. We use classic biochemistry, mutational analysis, and in vitro and in vivo assays to better understand the molecular interactions between the parasite and its mosquito and mammalian hosts. Our goal is to translate our findings to help develop treatments and a vaccine that target the malaria parasite.
The Randall Packard Lab investigates topics in the field of the history of medicine. Our current work seeks to explore the global history of dengue fever. Research is focused on the emergence and global spread of dengue as well as efforts to understand and control the disease. Part of our research involves establishing a better understanding of the complex biological, economic, environmental and social conditions that enabled the disease to rapidly expand worldwide during the 20th century.
Research in the Raymond Reid Lab focuses on community health and pediatric infectious diseases among Native American populations; epidemiologic studies of enteric infections, Haemophilus influenzae, and pneumococcus; and field testing of vaccines and treatments.
Research in the Richard Chaisson Lab primarily examines tuberculosis and HIV infection, with specific focus on global epidemiology, clinical trials, diagnostics and public health interventions. Our recent research has involved evaluating a molecular diagnostic test for tuberculosis in HIV patients; observing TB responses during treatment of pulmonary tuberculosis; and examining antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa.
The key research interests in the Robert Bollinger Lab include identifying biological and behavioral risk factors for HIV transmission as well as characterizing the clinical progression and treatment of HIV and related infectious diseases. We also have a long-standing interest in optimizing health care capacity and delivery in settings with limited resources. Our work includes implementing science research projects to explore the effectiveness of initiatives such as task-shifting, clinical education, distance learning and mobile health programs as a way to improve health care in these locations.
Research in the Robert Gilman Lab focuses on disease control. Our work led to the development of microscopic-observation drug-susceptibility (MODS), a rapid tuberculosis diagnostic technique. We continue to conduct infectious disease research based at Peru’s Universidad Peruana Cayetano Heredia.
Effective immune responses are critical for control of a variety of infectious disease including bacterial, viral and protozoan infections as well as in protection from development of tumors. Central to the development of an effective immune response is the T lymphocyte which, as part of the adaptive immune system, is central in achieving sterilization and long lasting immunity. While the normal immune responses is tightly regulated there are also notable defects leading to pathologic diseases. Inactivity of tumor antigen-specific T cells, either by suppression or passive ignorance allows tumors to grow and eventually actively suppress the immune response. Conversely, hyperactivation of antigen-specific T cells to self antigens is the underlying basis for many autoimmune diseases including: multiple sclerosis; arthritis; and diabetes. Secondary to their central role in a wide variety of physiologic and pathophysiologic responses my lab takes a broad-based approach to studying T cell re...sponses. view more
The Soloski Lab works to understand how infection can lead to the development of chronic immune-mediated diseases. Our lab studies the role of cellular immune response in controlling infection with gram-negative bacterial pathogens, such as Salmonella typhimurium. Our work has recently focused on the role of the intestinal mucosal immune compartment in controlling oral infection. This effort has identified a new unrecognized subset of T cells residing within the epithelial barrier that expands following infection. Current efforts concentrate on understanding the recognition properties and effector function of this T cell subset and determining if an analogous population exists in the human mucosa. We also strive to understand the human host immune response to infection with Borrelia burgdorfer, the causative agent of Lyme disease.
The O'Connor Lab studies the molecular basis of infectious disease using Legionella pneumophila pathogenesis as a model system.
We are looking at the network of molecular interactions acting at the host-pathogen interface. Specifically, we use L. pneumophila pathogenesis to examine the numerous mechanisms by which an intracellular bacterial pathogen can establish infection, how it exploits host cell machinery to accomplish this, and how individual proteins and their component pathways coordinately contribute to disease.
We are also studying the role of environmental hosts in the evolution of human pathogens. Using genetics and functional genomics, we compare and contrast the repertoires of virulence proteins required for growth in a broad assortment of hosts, how the network of molecular interactions differs between hosts, and the mechanisms by which L. pneumophila copes with this variation.
The mission of the Transplant and Oncology Infectious Diseases (TOID) Center is to expand institutional expertise in clinical and academic activities focused on infectious complications in transplant (solid organ and stem cell) and oncology patients at Johns Hopkins medical institutions. Key efforts include developing standardized algorithms for the prevention and treatment of infections in these vulnerable patients and to establish an expanded infrastructure to facilitate clinical and translational studies at TOID. Current research projects focus on diagnostics for invasive fungal infections and specialized studies of the pathogenesis of candidiasis and aspergillosis.
The Theresa Shapiro Laboratory studies antiparasitic chemotherapy. On a molecular basis, we are interested in understanding the mechanism of action for existing antiparasitic agents, and in identifying vulnerable metabolic targets for much-needed, new, antiparasitic chemotherapy. Clinically, our studies are directed toward an evaluation, in humans, of the efficacy, pharmacokinetics, metabolism and safety of experimental antiparasitic drugs.
Research in the Thomas Quinn Lab encompasses epidemiology, pathogenesis and clinical features of HIV/AIDS internationally, which includes the interaction between STDs and tropical diseases on the natural history and spread of HIV/AIDS in developing countries. Our recent research has examined the viral kinetics and transmission probabilities of HIV among discordant couples with the subsequent design and application of interventions, including therapy to prevent transmission of HIV. Molecular studies have mapped the molecular epidemic of HIV on a global basis, linking virologic changes to the spread of HIV and measuring the demographic impact of the epidemic.
Investigators in the Yukari Manabe Lab evaluate the accuracy of rapid, point-of-care diagnostics for HIV, tuberculosis and related infectious diseases in resource-limited settings particularly sub-Saharan Africa and examine the impact of diagnostic interventions on disease detection and patient outcomes. The team also conducts operational and translational research in tuberculosis and HIV co-infection.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
